Key result
Amygdalin enhances lapatinib lethality in breast cancer cells, driven by increased Bax protein expression.
Why the study?
HER-2 positive breast cancer is aggressive and often resistant to chemotherapy drugs like lapatinib, while amygdalin has shown antitumor effects in different cancer cells.
Amygdalin potentiates the cytotoxic effects of lapatinib in HER-2 positive breast cancer cells by increasing Bax expression, suggesting a potential combination strategy.
Should not change lapatinib use in HER2-positive breast cancer; hypothesis-generating for combination strategies needing clinical validation.
Background and Aim: : HER-2 Positive breast cancer is one of the aggressive types of cancer and is resistant to chemotherapy drugs such as lapatinib .Amygdalin is a natural compound found in the seeds of fruits such as apricot, peache, apple and almond. In recent years, antitumor effects of amygdalin have been reported in different types of cancer cells. The present study aimed to investigate the cytotoxic effectes of amygdalin in combination with lapatinib, on cell viability and Bax expression in SK-BR-3 breast cancer cell line as a cell line with high expression of HER-2. Material and Methods: After cell culture we evaluated the survival of SK-BR-3 cells by MTT after 48 hours of treatment with different concentrations of amygdalin and lapatinib alone and in combination. The pre-apoptotic Bax expression level was measured by western blot method. Results: Amygdalin and lapatinib significantly decreased survival of SK-BR-3 cells in a dose-dependent manner. The simultaneous use of amygdalin with lapatinib showed that amygdalin enhanced the lethal effect of lapatinib. Also, amygdalin at the concentration of 10 mg/ml increased the effects of 200 nM lapatinib on the expression of Bax protein. Conclusion: This study showed that the amygdalin-lapatinib combination could be effective for breast cancer patients with HER-2 overexpression. However, more studies are recommended to obtain more definitive results.
No takes yet. Share an insight, caveat, or question.
Bahman Moradi poodeh (2023) studied HER-2 Positive breast cancer. Amygdalin and lapatinib combination vs. Lapatinib alone, amygdalin alone, and untreated control was evaluated on Cell viability and Bax protein expression. The simultaneous use of 10 mg/ml amygdalin with lapatinib significantly enhanced the lethal effect of lapatinib and increased Bax protein expression in SK-BR-3 breast cancer cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: